Zum Inhalt springen

Cris Bergerot, PhD

@crisbergerot.bsky.social did:plc:c7uckvugvdgto5clyo7p63uh

Advancing oncology care through research, innovation, and multidisciplinary collaboration. Passionate about patient-centered solutions, PROs, HRQOL, and evidence-based practices, w a focus on #GUOnc, #GeriOnc & #PallOnc #ASCO25 FCOI: http://bit.ly/344gKxq

Bei Bluesky seit

Follower
544
Folgt
202
Posts
98
Tage in Ranglisten
0

Zusammenfassung

Cris Bergerot, PhD (@crisbergerot.bsky.social) ist seit 28 November 2024 auf Bluesky. Das Konto hat 544 Follower, folgt 202 Konten und hat 98 Posts veröffentlicht.

Ranglisten-Platzierungen

Die besten Tage, an denen Posts dieses Kontos in Debyas Tagesliste kamen.

Dieses Konto war noch in keiner Tagesrangliste.

Zuletzt gelikte Posts

Öffentliche Likes aus dem Bluesky-Netzwerk.

  • American Society of Clinical Oncology@ascocancer.bsky.social

    And the answer was ... D! Erdafitinib causes ocular toxicity; a baseline ophthalmic exam is required. Did you get it right? Let us know in the comments! Subscribe to ASCO-SEP® today: bit.ly/47OmqN7 ASCO members get 20% off; additional discounts available.

    Post anzeigen
  • American Society of Clinical Oncology@ascocancer.bsky.social

    New Living Guideline: Medical Therapy for Hormone Receptor-Positive, HER2-Negative Stage I to III Breast Cancer. The new Living Guideline covers the use of medical therapies for stage I-III hormone receptor-positive, HER2-negative breast cancer. Learn more: https://bit.ly/4spJjjv

    Post anzeigen
  • American Society of Clinical Oncology@ascocancer.bsky.social

    Dr. Sumanta Pal of @cityofhope.bsky.social and @ryannipp.bsky.social of OU Health Stephenson Cancer Center discuss high-impact research presented at #ASCOQLTY26 on the latest episode of the #ASCODailyNews Podcast: https://bit.ly/4zg53kt

    Post anzeigen
  • International Kidney Cancer Coalition@ikccorg.bsky.social

    We are proud to continue our partnership with the American Association for Cancer Research (AACR) to support the AACR Scholar-in-Training Award! 🗓️ Application Deadline: 10 November 2026 🔗 Learn more and apply: buff.ly/yx1Y0QV

    Post anzeigen
  • KidneyCAN@kidneycan.bsky.social

    No two #kidneycancer journeys are the same. Built with KidneyCAN & Eisai, Kompass can help guide you to tailored resources and support that fit where you are today. Explore for yourself at KidneyCancerKompass.com.

    Post anzeigen

Melde dich an, um mehr zu sehen

Blockierte Konten

Blockierungen sind auf Bluesky öffentlich.

Dieses Konto blockiert niemanden.